1. Home
  2. TEI vs ALT Comparison

TEI vs ALT Comparison

Compare TEI & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TEI
  • ALT
  • Stock Information
  • Founded
  • TEI 1993
  • ALT 1997
  • Country
  • TEI United States
  • ALT United States
  • Employees
  • TEI N/A
  • ALT N/A
  • Industry
  • TEI Finance Companies
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • TEI Finance
  • ALT Health Care
  • Exchange
  • TEI Nasdaq
  • ALT Nasdaq
  • Market Cap
  • TEI 282.9M
  • ALT 292.0M
  • IPO Year
  • TEI N/A
  • ALT N/A
  • Fundamental
  • Price
  • TEI $6.20
  • ALT $3.78
  • Analyst Decision
  • TEI
  • ALT Strong Buy
  • Analyst Count
  • TEI 0
  • ALT 6
  • Target Price
  • TEI N/A
  • ALT $17.40
  • AVG Volume (30 Days)
  • TEI 142.4K
  • ALT 3.0M
  • Earning Date
  • TEI 01-01-0001
  • ALT 08-12-2025
  • Dividend Yield
  • TEI 10.51%
  • ALT N/A
  • EPS Growth
  • TEI N/A
  • ALT N/A
  • EPS
  • TEI N/A
  • ALT N/A
  • Revenue
  • TEI N/A
  • ALT $20,000.00
  • Revenue This Year
  • TEI N/A
  • ALT N/A
  • Revenue Next Year
  • TEI N/A
  • ALT $761,880.20
  • P/E Ratio
  • TEI N/A
  • ALT N/A
  • Revenue Growth
  • TEI N/A
  • ALT N/A
  • 52 Week Low
  • TEI $4.35
  • ALT $2.90
  • 52 Week High
  • TEI $5.39
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • TEI 65.42
  • ALT 50.80
  • Support Level
  • TEI $6.07
  • ALT $3.54
  • Resistance Level
  • TEI $6.13
  • ALT $3.84
  • Average True Range (ATR)
  • TEI 0.07
  • ALT 0.18
  • MACD
  • TEI 0.01
  • ALT 0.06
  • Stochastic Oscillator
  • TEI 93.59
  • ALT 85.15

About TEI Templeton Emerging Markets Income Fund Inc.

Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: